Mathematical model for bone mineralization by Svetlana V. Komarova et al.
ORIGINAL RESEARCH
published: 21 August 2015
doi: 10.3389/fcell.2015.00051
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 August 2015 | Volume 3 | Article 51
Edited by:
Sunder Sims-Lucas,
University of Pittsburgh, USA
Reviewed by:
Kunsoo Rhee,
Seoul National University, South Korea
Shang Li,
Duke-NUS Graduate Medical School,
Singapore
*Correspondence:
Svetlana V. Komarova,
Shriners Hospital for Children-Canada,
1529 Cedar Avenue, Montreal, QC
H3G IA6, Canada
svetlana.komarova@mcgill.ca
†
Present Address:
Erica Zuhr,
Booz Allen Hamilton, Rockville, USA
Specialty section:
This article was submitted to
Cell Growth and Division,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 18 June 2015
Accepted: 04 August 2015
Published: 21 August 2015
Citation:
Komarova SV, Safranek L,
Gopalakrishnan J, Ou MY, McKee MD,
Murshed M, Rauch F and Zuhr E
(2015) Mathematical model for bone
mineralization.
Front. Cell Dev. Biol. 3:51.
doi: 10.3389/fcell.2015.00051
Mathematical model for bone
mineralization
Svetlana V. Komarova 1, 2*, Lee Safranek 3, Jay Gopalakrishnan 4, Miao-jung Yvonne Ou 5,
Marc D. McKee 1, 6, Monzur Murshed 1, 2, 7, Frank Rauch 2 and Erica Zuhr 8†
1 Faculty of Dentistry, McGill University, Montreal, QC, Canada, 2 Shriners Hospital for Children-Canada, Montreal, QC,
Canada, 3Department of Mathematics, Simon Fraser University, Burnaby, BC, Canada, 4 The Fariborz Maseeh Department of
Mathematics and Statistics, Portland State University, Portland, OR, USA, 5Department of Mathematical Sciences, University
of Delaware, Newark, DE, USA, 6Department of Anatomy and Cell Biology, Faculty of Medicine, McGill University, Montreal,
QC, Canada, 7Department of Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada, 8Department of
Mathematics, High Point University, High Point, NC, USA
Defective bone mineralization has serious clinical manifestations, including deformities
and fractures, but the regulation of this extracellular process is not fully understood.
We have developed a mathematical model consisting of ordinary differential equations
that describe collagen maturation, production and degradation of inhibitors, and
mineral nucleation and growth. We examined the roles of individual processes in
generating normal and abnormal mineralization patterns characterized using two
outcome measures: mineralization lag time and degree of mineralization. Model
parameters describing the formation of hydroxyapatite mineral on the nucleating centers
most potently affected the degree of mineralization, while the parameters describing
inhibitor homeostasis most effectively changed the mineralization lag time. Of interest,
a parameter describing the rate of matrix maturation emerged as being capable
of counter-intuitively increasing both the mineralization lag time and the degree of
mineralization. We validated the accuracy of model predictions using known diseases of
bone mineralization such as osteogenesis imperfecta and X-linked hypophosphatemia.
The model successfully describes the highly nonlinear mineralization dynamics, which
includes an initial lag phase when osteoid is present but no mineralization is evident,
then fast primary mineralization, followed by secondary mineralization characterized by a
continuous slow increase in bone mineral content. The developed model can potentially
predict the function for a mutated protein based on the histology of pathologic bone
samples from mineralization disorders of unknown etiology.
Keywords: bone histomorphometry, matrix mineralization, mineralization inhibitors, nucleating centers,
osteogenesis imperfecta, osteomalacia, X-linked hypophosphatemia, rickets
Background
Defects in bone mineralization can result in reduced or excessive bone mineralization, which
can lead to serious clinical manifestations, including bone deformities and fractures. Plasma
levels of calcium and phosphate—ionic mineral constituents of bone hydroxyapatite mineral—
as well as their key regulators parathyroid hormone, vitamin D and FGF23, are critically
important for successful mineralization (Shimada et al., 2004; Morris et al., 2012). Numerous
conditions which are not associated with abnormal levels of circulating calcium and phosphate
are also known to result in hypo- or hypermineralization of bone matrix (Roughley et al., 2003).
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One example is osteogenesis imperfecta, a disease usually caused
bymutations in collagen type I-encoding genes and characterized
by increased bone mineralization (Roschger et al., 2008a; Forlino
et al., 2011). The clinical phenotype of osteogenesis imperfecta
can also be caused by mutations in genes encoding the proteins
that are involved in collagen post-translational modifications
such as bone morphogenetic protein 1 (BMP1), or the proteins
that regulate bone mineralization by an as yet unknown
mechanism (Marini et al., 2014). The mechanisms underlying the
development of hypo- and hypermineralization of extracellular
bonematrix when the plasma levels of calcium and phosphate are
within the normal range are complex and not well understood.
Clinically, the mineralization process can be examined in
bone biopsy samples, which are typically obtained from the iliac
bone. When tetracycline labeling is performed prior to biopsy,
it is possible to assess the mineralization process quantitatively
using bone histomorphometry (Rauch, 2006). Key, well-accepted
histomorphometric descriptors of the mineralization process
include the average thickness of the layer of unmineralized
organic bone matrix (osteoid thickness) and the duration of the
lag time between the deposition of organic matrix and the start
of mineralization (mineralization lag time). Using quantitative
backscattered-electron imaging, it is also possible to determine
the average density of mineralized bone (Roschger et al., 2008b),
which among other measures indicates the proportion of the
mineralized tissue mass contributed to by the mineral ions.
The molecular origin and mechanistic basis of bone hypo-
and hypermineralization are incompletely understood; however,
it is clear that the process of mineralization is tightly regulated
and is highly nonlinear. The goal of this study was to develop
a simplified mathematical model of a complex process that
provides a description of basic steps in the mineralization
process, including collagen production and maturation, delivery
and degradation of inhibitors, as well as mineral nucleation and
growth. To our knowledge, no mathematical model focused on
bone mineralization process exists to date, however important
work has been performed in modeling the role of mineralization
process in determining the bone mineral distribution (Ruffoni
et al., 2007); the process of dentinogenesis including dentin
phosphoprotein-regulated mineralization (Niño-Barrera et al.,
2013) as well as describing the mineralization-induced changes
in mechanical properties of collagen (Crolet et al., 2005;
Nikolov and Raabe, 2008; Barkaoui and Hambli, 2014). Using
the intentionally simplified model which includes multiple
complexities in a limited number of variables, we were able
to capture the significant nonlinearity of the mineralization
process. Modeling predictions regarding the roles of individual
processes in generating abnormal mineralization patterns were
compared to the phenotype of diseases having in major
bone mineralization defects—namely osteomalacia diseases and
osteogenesis imperfecta.
Model Development
We modeled the changes over time in the concentration of
five key players in the mineralization process—the collagen
matrix subdivided into naïve and mature matrix, the inhibitors
of mineralization, the nucleation centers (nucleators), and the
hydroxyapatite mineral—within a homogeneous unit volume of
osteoid of ∼1µm3 in dimensions using a system of ordinary
differential equations. The following considerations were used to
identify the main model assumptions.
1. Physiologically, the formation of bone tissue begins with the
secretion of an organic bone matrix by osteoblasts, which to a
large extent (by weight and volume) consists of collagen type
I (Christiansen et al., 2000). Once this naïve organic matrix
is deposited into the extracellular compartment, it needs to
be processed in order to accommodate mineralization—a
process termed matrix maturation. This maturation phase
includes cleavage of C- and N-terminal propeptides from the
collagen molecule and collagen crosslinking and packaging
(Knott and Bailey, 1998; Christiansen et al., 2000), as well
as similar processing of noncollagenous proteins (Kaartinen
et al., 2002). The process of extracellular matrix maturation
lasts 10–14 days. For this model, we considered different steps
of matrix maturation such as post-translational modification
of collagen and noncollagenous matrix proteins, and collagen
cross-linking as a maturation process, which normally occurs
with a characteristic rate constant of k1. In themodel, a change
in any step of post-translational modification or crosslinking
is assumed to have an overall effect on matrix maturation by
either facilitating or interfering with the normal process. We
assumed that collagen matrix is produced by osteoblasts in a
naïve form (x1) that matures into a fully assembled mature
collagen matrix (x2). These relationships are described by
Equations (1a) and (1b).
2. The mineralization of naïve matrix is prevented by the
action of numerous inhibitors, which reside in the local
bone extracellular microenvironment, or arrive from the
circulation (Murshed and McKee, 2010). During matrix
maturation, the inhibitors are degraded or inactivated to
enable mineralization. For example, a potent small-molecule
inhibitor of mineralization—inorganic pyrophosphate—is
cleaved by alkaline phosphatase present on the osteoblast
cell membrane (Murshed and McKee, 2010). The proteins
of the SIBLING family (small integrin-binding ligand,
N-linked glycoproteins) are also known for their role in
the regulation of mineralization; for example, the SIBLING
proteins osteopontin (OPN) and matrix extracellular
phosphoglycoprotein (MEPE) are potent inhibitors of
mineralization (Rowe et al., 2004; Jahnen-Dechent et al.,
2008). The action of another SIBLING protein dentin matrix
protein 1 (DMP1) is regulated by its state during matrix
maturation. DMP1 acts an inhibitor of mineralization when
it is in solution (He et al., 2005), but becomes a promoter of
mineralization when absorbed onto collagen surfaces (Hunter
and Goldberg, 1993; Hunter et al., 1996; He et al., 2003).
We modeled the combined action of different inhibitors
of mineralization (I), which were assumed to be released
into the extracellular compartment near the cells (Murshed
and McKee, 2010) and diffuse through immature collagen
(Weinstock and Leblond, 1973) with the characteristic rate
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constant of v1. Thus, inhibitor availability was modeled to
be proportional to the amount of naïve collagen as described
by the term v1x1 in the Equation (1c). The concentration of
active inhibitors in mineralizing matrix gradually decreases
both because of their degradation through enzymatic cleavage
(Addison et al., 2008, 2010; Murshed andMcKee, 2010; Barros
et al., 2013) as well as removal by other processes that interfere
with inhibitor function, such as binding, masking or trapping
(He et al., 2005; David et al., 2011). In the model, inhibitor
removal/reduction occurs with the rate constant of r1 and is
stimulated by the presence of mature collagen matrix and as
described by the term r1x2I in the Equation (1c).
3. During the mineralization process calcium and phosphate
precipitate to form hydroxyapatite [Ca10(PO4)6(OH)2]
crystals within the organic bone matrix (Boskey and Posner,
1984). The location and orientation of individual crystals
is not random, but rather is guided by the chemistry and
structure of collagen and noncollagenous proteins and small
proteoglycans initiating and regulating crystal nucleation
and growth between and within collagen fibrils (George and
Veis, 2008). Within the collagen fibril the mineral is formed
in-between the assembled collagen molecules (intrafibrillar
mineralization) (George and Veis, 2008). Interfibrillar crystals
can be nucleated by the SIBLING proteins bone sialoprotein
and DMP1 (Hunter and Goldberg, 1993; Hunter et al., 1996;
He et al., 2003). We assumed that nucleation centers (N)
are required to initiate mineral precipitation (Hunter and
Goldberg, 1993; He et al., 2003), and that nucleators appear
during matrix maturation. The number of nucleators per
mature collagen molecule is k2. We assumed that intrafibrillar
and interfibrillar nucleators act in a similar way, therefore
when k2 = 1, there is only one intrafibrillar nucleator per 1
molecule of collagen, and when k2 > 1, then there is a mix of
intrafibrillar and interfibrillar nucleators. A resulting rate of
nucleator appearance is proportional to matrix maturation
given by Equation (1b) and is described by the term k2
dx2
dt
in
Equation (1d). We assume that after mineralization is
initiated by a given nucleator, this nucleator becomes a
mineral crystal and thus can maintain, but no longer can
initiate mineral precipitation (Hunter et al., 1996). Therefore,
whenmineraization starts, the number of nucleators decreases
as they become masked by the mineral. The rate of decrease
of nucleators was assumed to be proportional to the rate at
which mineralized crystals (y) appear (dy/dt), as well as to the
concentration of nucleators present, as described by the term
r2
dy
dt
N in Equation (1d).
4. The formation of mineral (y) was assumed to occur with a
characteristic rate of k3 and to be directly proportional to the
number of nucleators and inversely related to the amount
of inhibitors (Murshed and McKee, 2010). Although we
modeled matrix mineralization in a homogenous assumption,
it would be possible to relate the number of nucleators N
to the number of mineral crystals within a given volume of
the matrix, while the mineral growth rate k3 to the growth
of individual crystals. Particular considerations were given
to the function describing the effect of inhibitors on mineral
formation. We modeled mineralization rate by an equation of
the form
dy
dt
= k3g(I)N, where g(I) is a decreasing function
of I which tends to 0 as I goes to infinity. Mineralization
dynamics was qualitatively similar when g(I) was described
by the piecewise function g(I) = {
−aI + b, x ≤ 1
0, I > 1
} or the
Hill type functions g(I) = b
b+eaI
and g(I) = b
b+Ia
, (data
not shown). We chose a differentiable function amenable
for biological interpretation g(I) = b
b+Ia
with a = 10 and
b = 0.001. This function approaches 1 at I smaller than
∼0.4, which represents the critical (nondimensionalized)
value of I permitting mineralization in the
system.
Based on these assumptions (Figure 1), the changes in the
five components of the mineralizing bone matrix (Table 1)
are described by the following system of ordinary differential
Equations (1).
dx1
dt
= −k1x1 (1a)
dx2
dt
= k1x1 (1b)
dI
dt
= v1x1 − r1x2I (1c)
dN
dt
= k2
dx2
dt
− r2
dy
dt
N (1d)
dy
dt
= k3
(
b
b+ Ia
)
N (1e)
Estimation of Characteristic Values of the
Variables and Parameters
To estimate collagen packing within 1µm3 of matrix, we assume
that a single molecule of triple-helical collagen is 1.4 nm in
diameter and 300 nm in length based on estimates in the
literature (Gross et al., 1955; George and Veis, 2008). Collagen
molecules form fibrils of 70–90 nm in diameters, thus a single
fibril contains ∼3000 molecules (Hodge and Schmitt, 1960;
George and Veis, 2008). We assume that fibrils have a ∼10 nm
coating of noncollagenous proteins and small proteoglycans, thus
the cross-section of collagen fibrils is represented by circles of
110 nm diameter. In a hexagonal pattern circles have ∼0.9069
packing density (Steinhaus, 1999), and hence, (0.9069 × 106/(pi
× 552) ∼ 95.4 fibrils fit in a cross-section of 1µm2, and ∼3.3
molecules fit in the 1µm lengthwise. Therefore, in 1µm3 of
volume, there are 95.4 × 3.3 × 3000 = 9.4 × 105 molecules of
collagen.
To estimate the number of hydroxyapatite molecules, we
started with a density of fully mineralized bone of 2.0 g/cm3
(Gong et al., 1964). Assuming that bone contains 70% mineral,
the hydroxyapatite density is ∼1.40 g/cm3 = 1.40 ×10−12
g/µm3. Given the molecular weight of the hydroxyapatite
molecule [Ca10(PO4)6(OH)2] of 1004 g/mol, 1004 g contains
6 × 1023 molecules of hydroxyapatite. Therefore, 1µm3
of mineralized matrix contains ∼ 0.8 × 109 molecules of
hydroxyapatite.
The number of nucleators was first assumed to be of the
same order of magnitude as the number of collagen molecules
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(k2 = 1), and later we examined how changing the number of
nucleators affects the outcome of the mineralization. It is difficult
to estimate the number of inhibitors, since we pooled into this
category factors that use different mechanisms to achieve a single
function—inhibition of mineralization. These factors are much
smaller in size than the collagen molecules; however, there is less
physical space available for them, and therefore we assumed that
the numbers of inhibitor molecules and collagen molecules are of
the same order of magnitude.
The rate constant values were chosen based on the observation
that two main phases are present during bone mineralization:
a slow phase of matrix maturation and a relatively fast phase
of matrix mineralization (Boskey and Posner, 1984; George
and Veis, 2008; Murshed and McKee, 2010). To account for
this dynamic, we assumed that the rates of matrix maturation
and the related processes of inhibitor processing and nucleator
production are slower than the rates of mineral precipitation and
nucleator removal/reduction. Since collagen maturation takes
place by ∼10–14 days (Boskey and Posner, 1984; George and
Veis, 2008), the rate of collagen assembly k1 was estimated as 0.1
FIGURE 1 | Schematic representation of bone mineralization described
by the model. Thick lines represent the processes occurring during
mineralization. Dotted lines represent the regulatory effects of different
components on the mineralization process.
day−1. We assumed the rate of inhibitor delivery to be v1 = 0.1
day−1 and the rate of inhibitor degradation to be r1 = 2 × 10
−7
day−1 mol−1. We assumed that when nucleators are available,
and no inhibitors are present, mineralization occurs with a faster
rate than collagen assembly k3 = 1000 day
−1. An order of
magnitude for the rate of the nucleator use by mineralization
was r2 = 1.5–2 × 10
−8 mol−1. The parameter values for the
simulation of normal mineralization are given inTable 2. Further
details for model nondimensionalization and numerical analysis
are given in Supplementary Material.
Results
First, we examined the pattern of temporal changes in the five
variables for the parameters representing bone mineralization in
a healthy subject (Tables 1, 2). Naïve collagen, which initially
constituted 100% of all collagen in the system, was gradually
assembled into mature collagen, resulting in 80% conversion
within 20 days, and in complete maturation within 40–60 days
(Figure 2A). Inhibitors initially present in the naïve matrix were
sustained for the first 10 days and rapidly degraded with the
appearance of mature collagen (Figure 2B). Nucleating centers
produced with the mature collagen reached the maximum at∼10
days, and were removed with the offset of the mineralization
(Figure 2B). After a lag time of ∼10 days, the mineralization
first progressed rapidly followed by a continuous slow mineral
formation (Figure 2C). The normalized mineralization degree
of 1 (i.e., full mineralization) was reached ∼100 days after the
deposition of naïve collagen. Thus, the model describes the lag
time required for matrix maturation, the rapid mineralization
offset, and the continuous slow increase in mineralization with
time (Roschger et al., 2008b).
To model mineralization defects, we first examined the effect
of the rate of hydroxyapatite formation k3 on the mineralization
outcome (Figure 3). Changes in k3 predictably affected the
rate of mineral formation, but also strongly and proportionally
affected the degree of mineralization. A 3-fold decrease in
the rate of hydroxyapatite formation k3 resulted in a 3-fold
decrease in mineralization degree (Figures 3A,B), while a 3-
fold increase in k3 led to a 3-fold increase in mineralization
degree (Figures 3C,D). The robust effect of k3 on the degree of
mineralization is due to the fact that the removal of nucleators
from the model is regulated by two independent parameters—
the rate of hydroxyapatite formation (directly affected by k3),
and the efficiency of nucleator removal (r2), which remains high
even when k3 is low. Therefore, when the rate of hydroxyapatite
TABLE 1 | Variables used in Equation (1).
Variables Concentration represented Characteristic values
x1 Collagen matrix (molecules/µm
3 ) 9.4× 105 molecules/µm3
x2 Assembled collagen matrix (molecules/µm
3 ) 9.4× 105 molecules/µm3
I Inhibitor concentration (molecules/µm3 ) ∼106 molecules/µm3
N Nucleator concentration (molecules/µm3 ) 1–10 per 1 assembled collagen
y Hydroxapatite (molecules/µm3 ) 0.8× 109 molecules/µm3
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TABLE 2 | Parameters used in Equations (1) and (2).
Parameter Description Value Nondimensionalized
k1 Collagen assembly 0.1 day
−1 0.1
k2 Number of nucleators per collagen molecule 1 1
k3 Formation of hydroxyapatite molecules 1000 day
−1 1
υ1 Production of inhibitors by osteoblasts 0.1 day
−1 0.1
r1 Degradation of inhibitors 2× 10
−7 day−1 0.2
R2 Use of nucleators by mineralized bone 1.7× 10
−8mol−1 12
a Hill coefficient 10 10
b Apparent dissociation constant for Hill function 1057 0.001
FIGURE 2 | Changes in time in different players in the
mineralization process in healthy bone. (A) The concentrations of
naïve (x1, light green) and mature (x2, dark green) collagen matrix. (B)
The concentration of the mineralization inhibitor (I, orange) and the
nucleation centers (N, purple). (C) The concentration of mineral (y).
Indicated are the mineralization lag time, measured as a time delay
between time 0 and the onset of mineralization, and mineralization
degree, measured as the amount of mineral at time = 100 days. For the
simulation of healthy bone, the mineralization lag time is 10 days, and the
mineralization degree is 1.
formation decreases, the time interval during which nucleators
are present remains unchanged, resulting in a decrease in
mineralization degree. Changes in k3 did not affect the dynamics
of collagen maturation or turnover of its inhibitors.
Next we examined the role of parameters affecting the
nucleators, the number of nucleators per mature collagen k2,
and rate of removal of nucleators caused by hydroxyapatite
formation r2 (Figure 4). Mineralization lag time was not affected
by changes in k2 and r2, since the dynamics of collagen and
inhibitors does not depend on these parameters (Figures 4C,F).
A 3-fold decrease in the number of nucleators per mature
collagen k2 resulted in a 40% decrease in mineralization degree
(Figures 4A,C), while a 3-fold increase in k2 led to a 60% increase
in the mineralization degree (Figures 4B,C). A 3-fold decrease in
the rate of nucleator removal caused by hydroxyapatite formation
r2 resulted in an almost 2-fold increase in mineralization degree
(Figures 4D,F), while a 3-fold increase in r2 resulted in 40%
decrease in mineralization degree (Figures 4E,F).
To examine the effect of parameters affecting the homeostasis
of inhibitors on themineralization outcome, we changed the rates
of inhibitor production v1 and degradation r1 (Figure 5). Since
Equations (1a) and (1b) are not affected by these parameters,
no change in the degree or timing of collagen maturation was
evident following changes in v1 and r1. The rate of inhibitor
production v1 was changed 10-fold since smaller changes only
resulted in slight differences in the mineralization. A 10-fold
decrease in the rate of inhibitor production v1 resulted in a∼20%
decrease in mineralization lag time and a similar 20% increase
in mineralization degree (Figures 5A,C). A 10-fold increase in
the rate of inhibitor production v1 led to a 3-fold increase in
mineralization lag time and a 40% decrease in mineralization
degree (Figures 5B,C). The effect of changing the rate of inhibitor
degradation r1 onmineralizationmirrored the effects of changing
the rate of inhibitor production v1, however, smaller, 3-fold
alterations of r1 were required to obtain noticeable effects on
mineralization. A 3-fold decrease in r1 resulted in a sustained
inhibitor presence, a 2-fold increase in mineralization lag time
and 40% decrease in mineralization degree (Figures 5D,F). A 3-
fold increase in the rate of inhibitor degradation r1 resulted in a
2-fold decrease in the mineralization lag time and 20% increase
in mineralization degree (Figures 5E,F).
Finally, we examined the effect of changing the parameters
affecting initial collagen density x1(0) and maturation k1
on the mineralization outcome (Figure 6). Change in
the initial density of naïve collagen x1(0) represents an
altered ability of osteoblasts to produce collagen, or altered
collagen packing. A 3-fold decrease in x1(0) resulted in a
proportionally lower amount of mature collagen and the number
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FIGURE 3 | The effect of parameter affecting formation of
hydroxyapatite crystals k3 on the mineralization outcome. (A)
The effect of decreasing k3 3-fold. (B) Comparison of the
mineralization lag time and degree following decrease in k3 to
healthy mineralization. (C) The effect of increasing k3 3-fold. (D)
Comparison of the mineralization lag time and degree following
increase in k3 to healthy mineralization. The same color scheme is
used as in Figure 2.
of nucleators, leading to a 2-fold decrease in mineralization
degree (Figures 6A,C). In addition, the inhibitor presence
was sustained for a longer period of time leading to a 2-fold
increase in mineralization lag time (Figure 6A). A 3-fold
increase in x1(0) led to a 3-fold increase in the amount of
mature collagen and in the number of nucleators, which however
translated to only a 70-80% increase in mineralization degree
(Figures 6B,C).
A 3-fold decrease in the rate of collagen maturation k1
resulted in the persistence of naïve collagen for up to 100
days and sustained inhibitor presence, leading to an almost
3-fold increase in mineralization lag time (Figure 6D). After
mineralization started, it proceeded slower in the initial
phase than in control conditions (Figures 6D,F). However,
slow delivery of nucleators into the system resulted in a
decrease in the rate of their removal (when nucleators are
present at a low density, each of them can participate in
mineralization for a longer time since they interfere less with
each other). As a result, the mineralization rate did not
decrease with time and a notably increased mineralization
degree was reached (Figures 6D,F). A 3-fold increase in the
rate of collagen maturation resulted in faster elimination of
inhibitors and a slightly decreased mineralization lag time.
The initial mineralization proceeded faster; however, because
of faster removal of nucleators, it leveled off at lower overall
mineralization degree (Figures 6E,F).
Discussion
The mathematical model for bone mineralization developed
in this study captures the strongly nonlinear dynamics of
mineralization, which starts from a lag phase when osteoid is
present but nomineralization is evident, followed by fast primary
mineralization, and subsequent secondary mineralization
characterized by a continuous slow increase in bone mineral
content (Roschger et al., 2008b). This dynamic was achieved
in the model by assuming that (i) mineralization is suppressed
in the presence of inhibitors, (ii) mineralization occurs fast,
but requires the presence of nucleators, and (iii) nucleators
formed during collagen maturation are removed from the
system proportionally to the rate of mineralization. As a result,
the lag phase allows for accumulation of nucleators, so that
when inhibitors are reduced a large number of nucleators are
present allowing mineralization to proceed rapidly. However,
fast mineralization causes fast removal of nucleators leading
to a substantial decrease in mineralization rate with time.
We examined how changes in different parameters affect
mineralization dynamics. The parameters describing the
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FIGURE 4 | The effect of parameters affecting nucleator
production and removal on the mineralization outcome. (A–C)
The effect of decreasing 3-fold (A) or increasing 3-fold (B) the number
of nucleators per crosslinked collagen (k2). (C) Comparison of the
mineralization lag time and degree in conditions affecting k2 to healthy
mineralization. (D–F) The effect of decreasing 3-fold (D) or increasing
3-fold (E) the rate of use of nucleators by mineralized bone (r2). (F)
Comparison of the mineralization lag time and degree in conditions
affecting r2 to healthy mineralization. The same color scheme is used
as in Figure 2.
formation of hydroxyapatite crystals at the nucleating centers
potently affected the degree of mineralization, while the
parameters describing inhibitor homeostasis effectively changed
the mineralization lag time. Of interest, a single parameter
describing the rate of matrix maturation was capable of counter-
intuitively increasing both the mineralization lag time and the
degree of mineralization.
The model represents an intentional simplification of a
complexmineralization process, as we focused on simultaneously
capturing mineralization-related functions of many regulatory
molecules. Therefore, the following limitations should be
noted: (1) The model does not specify different steps of
matrix maturation, such as post-translational modification of
collagen and noncollagenous matrix proteins, and collagen
crosslinking. (2) The action of a large number of chemically
distinct inhibitors is pooled together as a single entity. (3)
Similarly, the difference in action of intrafibrillar and interfibrillar
nucleators is not described. (4) The model does not contain
the physical limitation for the maximal amount of mineral
that can be deposited into the matrix, and therefore its
long-term predictions should be interpreted with caution.
Model applicability at this stage is limited to situations when
the changes in mineralization dynamics are dramatic, while
further development of the model is required to predict
more subtle changes over time such as occurring during
development and in complex disorders of osteoporosis and
diabetes.
To compare the model predictions to the phenotype of
bone disorders known to result in abnormal mineralization,
we examined hypomineralization in osteomalacia and
hypermineralization in osteogenesis imperfecta. We used
the proportion of osteoid (osteoid volume per bone volume
OV/BV, and/or osteoid thickness O.Th.) as an indicator
of mineralization lag time, and bone mineral density
distribution (BMDD) (Roschger et al., 2008b) as a measure
of mineralization degree to relate the disease mineralization
phenotype observed on histomorphometric and BMDD analysis
to model predictions.
Application of the Model to Osteomalacia
Osteomalacia arises in part because of a systemic deficiency in
calcium and/or phosphate ions and the hormones responsible
for their regulation—vitamin D and FGF23. It is characterized
by an increase in mineralization lag time and a decrease in
mineralization degree (Arnala et al., 2001; Roschger et al.,
2003; Rabelink et al., 2011; Cheung et al., 2013). It is
assumed that the main cause of osteomalacia is a decreased
rate of hydroxyapatite formation (reflected by the parameter
k3 in the model) caused by a low level of calcium and/or
phosphate. However, the model predicts that a decrease in
k3 accounts only for a strong decrease in mineralization
degree, but cannot by itself affect the mineralization lag
time (as mineral formation starts only after the lag phase
is completed). In order to account for the strong increase
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FIGURE 5 | The effect of parameters affecting inhibitor
production and degradation on the mineralization outcome.
(A–C) The effect of decreasing 10-fold (A) or increasing 10-fold (B)
the rate of inhibitor production (v1). (C) Comparison of the
mineralization lag time and degree in conditions affecting v1to
healthy mineralization. (D–F) The effect of decreasing 3-fold (D) or
increasing 3-fold (E) the rate of inhibitor degradation (r1). (F)
Comparison of the mineralization lag and degree in conditions
affecting r1 to healthy mineralization. The same color scheme is
used as in Figure 2.
in the mineralization lag time, it is necessary to assume
additional direct or indirect effects of calcium/phosphate
deficiency on inhibitor homeostasis. In fact, increases in
local extracellular matrix mineralization inhibitors were also
shown to contribute to the development of osteomalacia
(Harmey et al., 2006; Barros et al., 2013; Millán, 2013).
Inorganic calcium and phosphate are known to affect osteoblast
differentiation (Beck et al., 2003; Dvorak et al., 2004),
which could in turn result in changes in expression and
processing of mineralization inhibitors. Deficiency in active 1,25-
dihydroxyvitamin D (1,25(OH)2D) often associated with rickets
(Takeda et al., 1997; Fukumoto, 2014) can affect the vitamin D
receptor-mediated expression of mineralization inhibitors such
as DMP1 (Nociti et al., 2014). Moreover, degradation of a strong
inhibitor of mineralization—pyrophosphate (Addison et al.,
2007)—is regulated by the concentration of phosphate, and both
phosphate and pyrophosphate regulate expression of osteopontin
(Harmey et al., 2006; Addison et al., 2007). In this context,
removal/reduction of inhibitory osteopontin and its inhibitory
peptides can be achieved by their extensive degradation by the
enzyme PHEX (Addison et al., 2010; Barros et al., 2013). The
model suggests that alteration of local inhibitor homeostasis is
as important for the development of osteomalacia as is the direct
effect of low calcium and phosphate on the rate of hydroxyapatite
formation.
Application of the Model to Osteogenesis
Imperfecta
Osteogenesis imperfecta (OI) is a disease characterized by
high bone fragility associated with low bone mass as well
as high mineral content in the bone tissue resulting in its
brittleness (Roschger et al., 2008a). Mutations in genes coding for
collagen type I—the usual cause of osteogenesis imperfecta—are
associated with hypermineralization and normal mineralization
lag time (Rauch et al., 2000). In the model, an increase in
the number of nucleators per molecule of collagen (k2) results
in an increase in mineralization degree but does not affect
the mineralization lag time. Therefore, the model suggests that
the hypermineralization in OI caused by mutations in type I
collagen-encoding genes is attributable to the increase in the
number of nucleators per molecule of collagen. This prediction
is consistent with a recent study that demonstrated that the
hydroxyapatite crystal size is similar in OI and control bone
tissue, thus implying that the increased mineral content in OI
must be due to an increased density of mineral crystals (Fratzl-
Zelman et al., 2014). Since in the model the density of nucleating
centers corresponds to the density of mineral crystals, we
conclude that the model correctly predicts hypermineralization
in OI due to mutations in genes coding for collagen type I.
Of interest, there are two distinct forms of OI in which
different mineralization phenotypes are described. In OI
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FIGURE 6 | The effect of parameters affecting collagen
maturation on the mineralization outcome. (A–C) The effect of
decreasing 3-fold (A) or increasing 3-fold (B) the amount of naïve
collagen deposited by osteoblasts at time = 0 (x1(0)). (C)
Comparison of the mineralization lag time and degree in conditions
affecting x1(0) to healthy mineralization. (D–F) The effect of
decreasing 3-fold (D) or increasing 3-fold (E) the rate of collagen
maturation (k1). (F) Comparison of the mineralization lag and degree
in conditions affecting k1 to healthy mineralization. The same color
scheme is used as in Figure 2.
caused by mutations in cartilage-associated protein (CRTAP)
a significant increase in the mineralization degree (Fratzl-
Zelman et al., 2010) and a marked reduction in mineralization
lag time (Morello et al., 2006) were observed. In contrast,
mutations in the collagen type I C-propeptide cleavage site give
rise to a hypermineralization accompanied by a simultaneous
increase in the mineralization lag time (Lindahl et al.,
2011).
CRTAP forms a complex with P3H1 and cyclophilin B which
3-hydroxylates the Pro986 residue of collagen alpha chains
(Chang et al., 2010). It was reported that CRTAP deficiency
results the deposition of abnormally structured collagen fibrils
(variable in diameter, with irregular borders) in skin samples
of OI patients due to CRTAP mutation (Valli et al., 2012). The
model predicts that an increase in the initial collagen density
(x1(0)) can result in hypermineralization accompanied by a
significant decrease in mineralization lag time. It is important
to stress that the model describes the changes occurring in the
already-deposited collagen, but not the rate of its deposition by
osteoblasts, which is negatively affected by CTRAPmutation. It is
indeed noticeable, that the distance between the collagen fibers in
the skin of a patient with CRTAP mutation appear to be smaller
(Valli et al., 2012). Thus, the CRTAP mutation likely affects the
packing of collagen molecules simultaneously resulting in (i) an
increase in trapping/masking and degradation of inhibitors, thus
shortening the mineralization lag time, and (ii) an increase in
the density of nucleators leading to an increase in mineralization
degree.
Mutation in the collagen C-propeptide cleavage site disrupts
extracellular collagen processing, resulting in decreased collagen
maturation rate (Lindahl et al., 2011), represented in our model
by the parameter k1. In the model, decrease in k1 uniquely
gave rise to the phenotype of increase in both mineralization
lag time and degree. Conversely, mutation in BMP1—an
enzyme that cleaves C-propeptide off procollagen—also results
in a decrease in collagen maturation, hyperosteoidosis and
hypermineralization (Hoyer-Kuhn et al., 2013). Thus, our model
predicted a correct, albeit counter-intuitive, mineralization
phenotype resulting from a decrease in the collagen matrix
maturation rate.
Conclusion
We have developed a simplified mathematical model that
describes changes in the mineralization of bone matrix when
individual processes occurring during mineralization are altered.
We validated the accuracy of model predictions using bone
diseases associated with dramatic changes in mineralization
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dynamics. During model development we used the data relevant
to the mineralization process in human bone and applied the
model to the analysis of human disorders of bone mineralization.
In the future, this model can be applied for qualitative predictions
of genotype/phenotype relationship in mouse models of bone
mineralization, and it can be adapted to study mineralization
of other calcified tissues, such as tooth dentin, cementum and
enamel.
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